|
Q-1363
|
Tuesday, June 16, 2026 |
With regard to SV40 promoter-enhancer fragments detected in certain COVID-19 vaccines: (a) what scientific evidence, studies, or data is Health Canada relying on to determine that any SV40 fragments present are inactive or non-functional;
(b) when did Health Canada first become aware of the significant increase in reported deaths to the United States' Vaccine Adverse Event Reporting System in 2021 and 2022 compared to previous years; and
(c) what actions, if any, did Health Canada take upon becoming aware of the increase in (b)? |
Awaiting response |
Monday, September 21, 2026 |
|
Q-1362
|
Tuesday, June 16, 2026 |
With regard to COVID-19 vaccines approved by Health Canada, including all initial approvals, amendments, expansions of indications, and subsequent authorizations (such as for booster doses or new age groups): (a) for each vaccine approved for COVID-19 (i) what was the vaccine name and manufacturer, (ii) what was the date the vaccine was approved, or the authorization was amended or expanded, (iii) what age groups did each approval or amendment apply to; and (b) for each approval or amendment in (a)(ii), (i) was it made under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19, made by the Minister of Health on September 16, 2020, (ii) was it made in full compliance with section C.08.002(2) of the Food and Drug Regulations, C.R.C., c. 870 (the Regulations), including full compliance with paragraphs C.08.002(2)(g) and (h), (iii) was it was made as a designated COVID-19 drug (while that term was included in the Regulations), or as a public health emergency drug (as currently defined in the Regulations), (iv) was subsection C.08.002(2.1) applied, (v) was subsection C.08.002(2.2) applied, (vi) was subsection C.08.002(2.3) applied, (vii) was subsection C.08.002(2.4) applied, (viii) was subsection C.08.002(2.5) applied? |
Awaiting response |
Monday, September 21, 2026 |
|
Q-968
|
Thursday, March 19, 2026 |
With regard to the COVID-19 vaccine mandates for public service employees, contractors and temporary workers, announced in October 2021 and those for federally regulated companies announced in December 2021: (a) did the government classify this policy as a public-health measure under the Public Health Agency of Canada Act, a human-resources requirement under the Financial Administration Act or as an occupational safety preventive measure under Part II of the Canada Labour Code; (b) which ministers, deputy ministers and senior officials approved the final classification of the vaccination policy, and, for each, what was (i) their name, (ii) their title, (iii) the date of the approval; (c) what hazard-identification or residual-risk assessments were performed under Canada Occupational Health and Safety Regulations sections 10.4 to 10.6 to determine whether existing controls such as hand sanitization, barriers, masking, distancing and disinfection were inadequate before escalation to mandating the COVID-19 vaccine; (d) were Policy and Workplace Health and Safety Committees consulted under Canada Occupational Health and Safety Regulations section 10.8 and section 125(1)(z.14) of the Code prior to implementation of the COVID-19 vaccine mandate, and, if so, for each meeting, what are the details, including the (i) date, (ii) list of attendees, (iii) outcome of the meeting, (iv) internal tracking or file number of the minutes; (e) did any federal department submit a notice or obtain approval under Canada Occupational Health and Safety Regulations section 12.04(1) when introducing the COVID-19 vaccine mandate as a biological preventive measure, and what documentation demonstrates compliance with 12.04(3) that the measure itself “did not create or contribute to a hazard”; (f) did Department of Justice Canada, Employment and Social Development Canada, Health Canada or the Treasury Board Secretariat issue any legal opinions or interpretive memos clarifying whether COVID-19 vaccination constituted “personal protective equipment” or was otherwise subject to Part II of the Canada Labour Code, and, if so, for each opinion or memo (i) what was the date, (ii) what was the name of the issuer, (iii) who received the information, (iv) on what date was it tabled in the House of Commons; (g) did Employment and Social Development Canada Occupational Health and Safety Officers revise 2020 findings that the existing hierarchy of control measures under section 122.2 of the Canada Labour Code were adequate, and, if so, for each revision what was the (i) date of the revision, (ii) reason for revision, (iii) evidence to justify the revision; (h) did the Minister of Labour determine that COVID-19 vaccination qualified for introduction at the third stage of the hierarchy, in section 122.2 of the Canada Labour Code requiring hazard elimination or reduction before resorting to personal protective equipment, and, if so, what analysis supported that decision; (i) following the Prime Minister’s 2021 announcement that the COVID-19 vaccine policy aimed to “protect the safety of our workplaces,” did the government classify the COVID-19 vaccine mandate measure as falling within its Part II duties to protect employees at work, and how was that classification conveyed to departments; (j) were employees explicitly informed that the COVID-19 vaccine mandate was implemented to protect workplace health and safety and therefore that their rights under sections 125 to 128, including the right to know, participate and refuse dangerous work, would apply, and, if not, why not; (k) which departments maintain records of federal employee exposures or adverse reactions resulting from the mandatory COVID-19 vaccine mandate policy pursuant to section 125(1)(j), how many reports were made and what is the schedule for retention and reporting; (l) which departments participated in interdepartmental meetings to coordinate the workplace COVID-19 vaccination policy, and which department led the decision to classify it as a public-health or human-resources measure rather than occupational protective equipment; (m) does the government plan to propose amendments to Part II of the Canada Labour Code or to the Canadian Occupational Health and Safety Regulations to clarify the classification of biological or pharmacological interventions in workplace safety programs; (n) did the Minister of Labour consult the National Advisory Committee on Occupational Safety and Health with respect to sections 122.2 and 124 of the Canada Labour Code regarding compliance before introducing medical or biological measures as occupational controls; (o) did the Minister of Health, Health Canada or the Public Health Agency of Canada have knowledge that biochemical components of the COVID-19 vaccines were registered chemicals, and, if so, on what date did they inform all federal employees of these chemicals under section 125.1 of the Canada Labour Code; and (p) was the mandatory vaccination policy for federal workers classified as a workplace safety measure under Part 2 of the Canada Labour Code, and, if so, on what dates were employees informed to document and report all adverse events, related to vaccination to the provincial worker's compensation boards for review? |
Answered |
Wednesday, May 6, 2026 |
|
Q-849
|
Monday, February 9, 2026 |
With regard to the Public Health Agency of Canada’s “Cases Following Vaccination” reports published from August 2021 to September 2022: (a) why did the Public Health Agency of Canada decide to begin calculating and comparing COVID-19 deaths using vaccination status, on the date of COVID-19 vaccine approval in December 2020, rather than the date on which each corresponding dose level actually began to be administered, or using weekly death counts, as is done for Statistics Canada’s Deaths by Age and Deaths by cause statistics; (b) what internal documentation, analyses, and external scientific or technical references were consulted to inform the methodological choice described in (a); (c) within the Public Health Agency of Canada, which organizational units and officials or governing authorities (i) proposed the methodology described in (a), (ii) reviewed it (including any internal methodological or ethics review), (iii) formally approved it for use in the “Cases Following Vaccination” reports; (d) in what way does the methodology described in (a) permit the observation and analysis of time-based (for example, weekly or seasonal) variations in COVID-19 deaths by vaccination status in relation to contemporaneous factors, including, but not limited to, seasonal changes and the dates on which additional vaccine doses (for example, second, third, or booster doses) began to be administered; and (e) in developing and approving this methodology, did the Public Health Agency of Canada rely on, or explicitly reference, any guidance, standards, or methodologies issued by the World Health Organization or any other international public health body, and, if so, which specific documents or authorities were relied upon? |
Answered |
Monday, April 13, 2026 |
|
Q-848
|
Monday, February 9, 2026 |
With regard to Health Canada, Public Health Agency of Canada and National Advisory Committee on Immunization expenditures between 2020 and 2023: (a) which projects and departments researched the safety of the COVID-19 vaccines and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost; (b) which projects and departments researched manufacturers' COVID-19 vaccine applications and how much did each project cost, broken down by (i) vaccine name, (ii) project name, (iii) department name, (iv) start date, (v) completion date, (vi) cost; (c) which projects and departments informed Canadians and specialists about the adverse events associated with the COVID-19 vaccines, broken down by (i) project name, (ii) department name, (iii) adverse event, (iv) start date, (v) completion date, (vi) date Canadians were informed about the adverse event, (vii) cost; and (d) which projects and departments researched vaccine hesitancy and how much did each project cost, broken down by (i) project name, (ii) department name, (iii) start date, (iv) completion date, (v) cost? |
Answered |
Monday, April 13, 2026 |
|
Q-752
|
Tuesday, December 9, 2025 |
With regard to preparations made by the government for witnesses representing the Department of Industry, who appeared or were scheduled to appear before parliamentary committees, since October 1, 2025: (a) were any off-site meetings or retreats held for the purpose of committee preparations in any way; (b) if the answer to (a) is affirmative, what are the details, including, for each, the (i) date, (ii) location, (iii) list of attendees, (iv) scheduled date and subject of the related committee meeting, (v) name of the related committee; (c) what were the expenditures related to each such meeting or retreat, in total, and broken down by item; (d) what are the details of any contracts signed in relation to off-site meetings, retreats or preparations, including any contracts with consultants who were involved with the preparations in any way, including, for each, the (i) date, (ii) vendor, (iii) amount, (iv) description of the goods or services, (v) location, if applicable, (vi) date and name of the related committee meeting or scheduled committee meeting; (e) what are the details of any contracts signed in relation to on-site meetings, retreats or preparations, including any contracts with consultants who were involved with the preparations in any way, including, for each, the (i) date, (ii) vendor, (iii) amount, (iv) description of the goods or services, (v) location, if applicable, (vi) date and name of the related committee meeting or scheduled committee meeting; and (f) are there any other contracts related to committee preparation not covered by (d) or (e), and, if so, what are the details of each, including the (i) date, (ii) vendor, (iii) amount, (iv) description of the goods or services, (v) location? |
Answered |
Monday, January 26, 2026 |
|
Q-748
|
Tuesday, December 9, 2025 |
With regard to supervised consumption sites approved by Health Canada, broken down by year: (a) has the Deputy Minister of Health, Greg Orencsak, visited any supervised consumption sites in his current role, and, if so, for each visit, what (i) was the date, (ii) were the name and location of the site; (b) has the Assistant Deputy Minister, Controlled Substances and Cannabis Branch, Kendal Weber, visited any supervised consumption sites in her current role, and, if so, for each visit, what (i) was the date, (ii) were the name and location of the site; (c) has the current Minister of Health visited any supervised consumption sites in her current role, and, if so, for each visit, what (i) was the date, (ii) were the name and location of the site; and (d) has the President of the Public Health Agency of Canada, Nancy Hamzawi, visited any supervised consumption sites in her current role, and, if so, for each visit, what (i) was the date, (ii) were the name and location of the site? |
Answered |
Monday, January 26, 2026 |
|
Q-580
|
Monday, November 17, 2025 |
With regard to COVID-19 vaccine mandates for public service employees, contractors and temporary workers: (a) how many employees and temporary workers were terminated because they didn't have the COVID-19 vaccine, broken down by (i) department, (ii) role, (iii) employment type (full-time, temporary, contractor); (b) how many employees and temporary workers had their pay suspended because they didn't have the COVID-19 vaccine, broken down by (i) department, (ii) role, (iii) employment type (full-time, temporary, contractor); (c) were grievances filed against the government for the COVID-19 vaccine employment mandates; (d) if the answer to (c) is affirmative, for each grievance, (i) what is the department, (ii) what is the role, (iii) what is the grievance, (iv) what is the state of the grievance, (v) what is the amount of money paid to the employee, (vi) did the government apologize for their actions; (e) did the government receive religious exemption requests for the COVID-19 employment vaccine mandate; and (f) if the answer to (e) is affirmative, how many religious exemption requests were received, broken down by (i) department, (ii) result of the request, (iii) who reviewed the exemption request? |
Answered |
Monday, January 26, 2026 |
